Historical Stock Chart
2 Months : From Jun 2019 to Aug 2019
By Dave Sebastian
Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug Administration has approved its Recarbrio drug injection for urinary-tract and intra-abdominal bacterial infections.
The New Jersey pharmaceutical company said it anticipates to make Recarbrio available later this year.
The drug is a combination of imipenem and cilastatin--both antibacterial components--as well as relebactam, which protects imipenem from certain enzymes, Merck said.
Relebactam received the FDA's Qualified Infectious Disease Product designation for the treatment of complicated urinary tract and complicated intra-abdominal bacterial infections, and the FDA gave Recarbrio's drug application a priority-review designation, the company said.
Write to Dave Sebastian at email@example.com
(END) Dow Jones Newswires
July 17, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.